A statistical analysis plan for the Adjunctive Corticosteroids for Tuberculous meningitis in HIV-positive adults (ACT HIV) clinical trial.
Donovan, Joseph;
Khanh, Trinh Dong Huu;
Thwaites, Guy E;
Geskus, Ronald B;
ACT HIV investigators;
ACT HIV investigators;
(2021)
A statistical analysis plan for the Adjunctive Corticosteroids for Tuberculous meningitis in HIV-positive adults (ACT HIV) clinical trial.
Wellcome open research, 6.
280-.
ISSN 2398-502X
DOI: https://doi.org/10.12688/wellcomeopenres.17154.2
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
TBM is the most severe form of tuberculosis. Clinical trial data are required to provide an evidence base for adjunctive dexamethasone in HIV-positive individuals with TBM, and to guide clinical practice. This document details the planned analyses at 12 months post randomisation for the ACT HIV clinical trial (NCT03092817); 'a randomised double-blind placebo-controlled trial of adjunctive dexamethasone for the treatment of HIV co-infected adults with tuberculous meningitis (TBM)'. The primary endpoint of the ACT HIV trial is death (from any cause) over the first 12 months after randomisation. This statistical analysis plan expands upon and updates the analysis plan outlined in the published study protocol.